Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q2TAL8
UPID:
QRIC1_HUMAN
Alternative names:
Glutamine-rich protein 1
Alternative UPACC:
Q2TAL8; Q4G0F7; Q7L621; Q8TEA5
Background:
Transcriptional regulator QRICH1, also known as Glutamine-rich protein 1, plays a pivotal role in the integrated stress response (ISR) by regulating protein homeostasis under ER stress conditions. It influences the unfolded protein response (UPR), crucial for cell viability, by modulating transcriptional programs related to protein translation and secretion-mediated proteotoxicity. Additionally, QRICH1 is involved in chondrocyte hypertrophy, essential for longitudinal bone growth.
Therapeutic significance:
Given its central role in ER stress-mediated inflammatory diseases and Ververi-Brady syndrome, targeting QRICH1 offers a promising avenue for therapeutic intervention. Understanding the role of Transcriptional regulator QRICH1 could open doors to potential therapeutic strategies.